COVID-19 displays significant inter-individual clinical variability, ranging from silent infection to lethal disease. We therefore need to characterize the role of human genetics in determining clinical response.
This work, comprising a series of cohort-based sub projects, aims to better characterize the role of human genetics in COVID-19 disease, deliver new biomarkers that predict people at highest risk, and implement appropriate healthcare strategies, including potential precision therapies.
As Canada’s national facility for genome sequencing and analysis, CGEn is leading HostSeq, working with partners across the country. CGEn is mandated to develop regional, national, and international linkages to ensure that this investment has maximal impact for the health of all Canadians.
Click here to learn more about the governance of CanCOGeN HostSeq.